Humanized monoclonal antibody that binds IgE to prevent its binding to the high affinity IgE receptor and blocking IgE mediated allergic response and inflammation in Bronchial Asthma is:: (A) Palivizumab, (B) Natalizumab, (C) Omalizumab, (D) Etilizumab
Answer is C. An anti-IgE preparation, Omalizumab, is approved by the FDA for use as an add-on therapy in children >=12 yr who have moderate to severe allergic asthma that is difficult to control.